Akari Therapeutics to Showcase ADC Pipeline at Webull Virtual Conference
Event summary
- Akari Therapeutics will present at Webull Financial's Corporate Connect Webinar Series on February 10, 2026, at 1:00 PM EST.
- CEO Abizer Gaslightwala will discuss the company's next-generation ADC platform and lead program AKTX-101, targeting a first-in-human trial by late 2026 or early 2027.
- The presentation will also cover AKTX-102, an additional ADC program focused on GI and lung cancers.
The big picture
Akari Therapeutics' participation in the Webull conference highlights its focus on showcasing its innovative ADC platform to a broader investor audience. The company's emphasis on RNA-splicing payloads positions it uniquely in the competitive oncology space, where next-generation ADCs are gaining traction. The strategic timing of the presentation, ahead of potential clinical milestones, underscores the importance of investor engagement in biotech financing.
What we're watching
- Clinical Development
- The pace at which Akari Therapeutics advances AKTX-101 into first-in-human trials will determine its competitive positioning in the ADC space.
- Market Reception
- How investors respond to the company's presentation and pipeline updates could impact its market valuation and access to capital.
- Pipeline Expansion
- Whether Akari can successfully develop and advance AKTX-102 alongside AKTX-101 will be critical for its long-term growth strategy.
Related topics